GADOLIN

July 6, 2016July 6, 2016

Non-Hodgkin Lymphoma Shows Significantly Better Outcomes with Obinutuzumab, Bendamustine Combo

News

Patients with non-Hodgkin lymphoma (NHL) who are resistant to rituximab therapies show greater benefits when treated with a obinutuzumab and bendamustine combination, compared to the standard bendamustine alone, according to data from the ... Read more

May 3, 2016May 3, 2016

CHMP Supports EU Approval of Obinutuzumab (Gazyvaro) to Treat Follicular Lymphoma

News

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy, to treat select patients with follicular lymphoma. The recommendation is as treatment for ... Read more

March 1, 2016May 13, 2016

FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan

News

Genentech announced that the the U.S. Food and Drug Administration (FDA) has approved the combination of Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva for the treatment of people with follicular lymphoma who were ... Read more

November 9, 2015May 13, 2016

Genentech’s Lymphoma Trial Results to Be Key Focus of ASH Meeting

News

Genentech recently announced that more than 45 abstracts, including eight of its approved or investigational medicines, will be presented during the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, set ... Read more